On July 24, 2025, the Federal Trade Commission (“FTC”) and the U.S. Department of Justice (“DOJ”) convened the second of three public listening sessions aimed at identifying barriers to drug price competition in the U.S....more
7/29/2025
/ Antitrust Provisions ,
Biosimilars ,
Competition ,
Department of Justice (DOJ) ,
Drug Pricing ,
Executive Orders ,
Federal Trade Commission (FTC) ,
Generic Drugs ,
Healthcare ,
Healthcare Reform ,
Pharmaceutical Industry ,
Prescription Drugs
President Trump was sworn into office on Monday, promising swift action on several fronts. There is already a new Federal Trade Commission (“FTC”) Chair, Andrew Ferguson, with former FTC Chair Lina Khan expected to step down...more
1/23/2025
/ Acquisitions ,
Antitrust Division ,
Competition ,
Department of Justice (DOJ) ,
Enforcement Actions ,
Federal Trade Commission (FTC) ,
Healthcare ,
Merger Controls ,
Mergers ,
Pharmaceutical Industry ,
Private Equity
The Department of Health and Human Services (HHS) and the Department of Justice (DOJ) recently released its “Health Care Fraud and Abuse Control Program Annual Report for Fiscal Year 2022” (the “Report”), highlighting...more
For a brief moment in time last April, the U.S. Food and Drug Administration’s (“FDA”) approval of the commonly-used abortion medication, Mifepristone, was curtailed. Just days after a Texas federal judge’s ruling suspended...more
6/16/2023
/ Abortion ,
Class Action ,
Department of Justice (DOJ) ,
Dobbs v. Jackson Women’s Health Organization ,
Food and Drug Administration (FDA) ,
Health Care Providers ,
Healthcare ,
Pharmaceutical Industry ,
Planned Parenthood of Southeastern Pennsylvania v Casey ,
Prescription Drugs ,
Roe v Wade ,
SCOTUS ,
Texas
The U.S. Food and Drug Administration’s (“FDA”) approval of the commonly-used abortion medication, Mifepristone, has been curtailed following dueling federal court decisions in Texas and Washington. Just days after a Texas...more
4/17/2023
/ Abortion ,
Department of Justice (DOJ) ,
Dobbs v. Jackson Women’s Health Organization ,
Executive Branch ,
FDA Approval ,
Food and Drug Administration (FDA) ,
Health Care Providers ,
Patient Access ,
Pregnancy ,
Prescription Drugs ,
Reproductive Healthcare Issues ,
State and Local Government